Clinical Trials on Solid Tumor With p53 Wild Type Status
Total 1416 results
-
Novartis PharmaceuticalsCompletedSolid Tumor With p53 Wild Type StatusFrance, Germany, Singapore, Switzerland, United States
-
Suzhou Genhouse Bio Co., Ltd.Not yet recruitingPatient With Advanced Solid TumorChina
-
Novartis PharmaceuticalsRecruitingContinued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid MalignanciesSpain, United States, Taiwan, Singapore, France
-
Chinese PLA General HospitalZhejiang UniversityRecruitingLymphoma | Solid Tumor, Adult | EphA2 Overexpression | TP53 R273H | TP53 R175H | TP53 R248Q | TP53 R249SChina
-
Brugmann University HospitalCompletedElderly Patients With a Solid TumorBelgium
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedSolid Tumors With Oligometastatic SpreadCanada
-
Elevar TherapeuticsBukwang Pharmaceutical, Co., Ltd.CompletedCancer Patients With Solid TumorsKorea, Republic of, United States
-
Frontier Medicines CorporationRecruitingColorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C MutationsUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedPediatric Patients With Solid TumorsUnited States
-
3H (Suzhou) Pharmaceuticals Co., Ltd.Not yet recruitingSolid Tumors With FGFR2 Alterations, AdultUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingPatients With Advanced Solid TumorsChina
-
Beijing InnoCare Pharma Tech Co., Ltd.Not yet recruitingPatients With Advanced Solid TumorsChina
-
Bio-Thera SolutionsGeorge Clinical Pty LtdActive, not recruiting
-
3H (Suzhou) Pharmaceuticals Co., Ltd.Not yet recruitingSolid Tumors With FGFR2 Alterations, AdultChina
-
Beijing InnoCare Pharma Tech Co., Ltd.Recruiting
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingPatients With Advanced Solid TumorsChina
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting
-
Beijing Tide Pharmaceutical Co., LtdRecruitingPatients With Advanced Solid TumorsChina
-
PharmaMarRecruitingPatients With Advanced Solid TumorsSpain
-
Shanghai Changzheng HospitalNot yet recruitingAdvanced Solid Tumors With Neuroendocrine Differentiation
-
Sichuan Kelun Pharmaceutical Research Institute...RecruitingSelected Subjects With Advanced Solid TumorsChina
-
Tianjin Hemay Oncology Pharmaceutical Co., LtdRecruitingPatients With Advanced Stage Solid TumorsChina
-
Deciphera Pharmaceuticals LLCTerminatedMetastatic Solid Tumors | Locally Advanced Tumors | Cancers With MET Genomic Alterations | Cancers With TRK Genomic AlterationsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPatients With Advanced or Metastatic Solid TumorsFrance
-
D3 Bio (Wuxi) Co., LtdRecruitingAdvanced Solid Tumors With MAPK Pathway MutationsAustralia, China, United States
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 MutationFrance, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
-
Disphar International B.V.CompletedPatients With Advanced or Metastatic Solid Tumors
-
BeiGeneCompletedFor Participants With Advanced Solid Tumors Failed With Previous Lines of TreatmentAustralia
-
Vall d'Hebron Institute of OncologyBanc de Sang i TeixitsRecruiting
-
Taiho Oncology, Inc.TerminatedAdvanced Solid Tumors With HER2 Abnormalities | Advanced Solid Tumors With HER3 AbnormalitiesUnited States, Spain, France, United Kingdom
-
Vanquish Oncology, Inc.University of Illinois at ChicagoCompletedSolid Tumor | Neuroendocrine Tumors | Pancreatic Neuroendocrine TumorUnited States
-
Suzhou Genhouse Bio Co., Ltd.Shanghai East Hospital; Shandong Tumor HospitalRecruitingAdvanced Solid Tumors With MAPK Signal Pathway MutantChina
-
IconOVir BioRecruitingPatients With Advanced Solid TumorsUnited States
-
AnHeart Therapeutics Inc.RecruitingIDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid TumorCholangiocarcinoma With IDH1 Mutation | Solid Tumors With IDH1 MutationChina
-
Taiho Oncology, Inc.TerminatedAdvanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating MutationsUnited States, United Kingdom, Austria, France
-
Vall d'Hebron Institute of OncologyHospital del Mar; Fundació Institut de Recerca de l'Hospital de la Santa Creu...RecruitingQuality of Life | Solid Tumor | Artificial Intelligence | Tumor | Oncology | Comorbidities and Coexisting Conditions | Mental Status Change | Nutrition Related Neoplasm/CancerSpain
-
PlexxikonTerminatedSolid Tumor | Tenosynovial Giant Cell Tumor | Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion MutationsUnited States
-
Eli Lilly and CompanyRecruitingRelapsed Solid Tumor | Refractory Solid TumorUnited States, Canada, Australia, Belgium, France, Spain, Germany, Italy
-
Massachusetts General HospitalBoehringer Ingelheim; Incyte CorporationNot yet recruitingCholangiocarcinoma | Advanced Solid Tumor | Metastatic Solid Tumor | Unresectable Solid TumorUnited States
-
Jiangsu Simcere Pharmaceutical Co., Ltd.RecruitingAdvanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene FusionChina
-
AmgenActive, not recruitingAdvanced/Metastatic Solid Tumors With KRAS p.G12C MutationTaiwan, Hong Kong
-
Bio-Thera SolutionsPeking University Cancer Hospital & InstituteRecruitingMelanoma | Advanced Solid TumorChina
-
St. Jude Children's Research HospitalRecruitingHepatocellular Carcinoma | Pediatric Cancer | Malignant Solid Tumor | Fibrolamellar Carcinoma | Pediatric Solid Tumor | Refractory Solid TumorUnited States
-
JS InnoPharm, LLCRecruiting
-
Jazz PharmaceuticalsCompletedAdvanced Solid Tumor | Metastatic Solid Tumor | Urothelial Cancer | Poorly Differentiated Neuroendocrine Carcinomas | Homologous Recombination Deficient-Positive Malignancies AgnosticUnited States
-
Ascentage Pharma Group Inc.CompletedPatients With Advanced Solid Tumor or LymphomaUnited States
-
PfizerTerminatedAvelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid TumorsUnited States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
-
Millennium Pharmaceuticals, Inc.CompletedMelanoma | Solid Tumor | Metastatic Melanoma | NeoplasmUnited States, United Kingdom
-
IpsenCompletedNeuroendocrine Tumour With Carcinoid SymptomsDenmark, Norway, Sweden
-
University of California, DavisCompletedUnspecified Childhood Solid Tumor, Protocol Specific | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Cognitive/Functional Effects | Long-term Effects Secondary to Cancer Therapy in Children | Long-term Effects Secondary to Cancer Therapy in Adults and other conditionsUnited States